Expired activity
Please go to the PowerPak
homepage and select a course.
Pharmacists, opioid safety, take-home naloxone, and preventing overdose
This activity is jointly provided by Postgraduate Institute for Medicine and the Substance Abuse and the Mental Health Services Administration (SAMHSA).
FACULTY
CO-AUTHORS
Brandie N. LeBlanc, BSN, CCRN
Clinical Lab Assistant, Pharmacy Practice
East Tennessee State University, Bill Gatton College of Pharmacy
Johnson City, Tennessee
Sarah T. Melton, PharmD, BCPP, BCACP, CGP, FASCP
Associate Professor of Pharmacy Practice
Department of Pharmacy Practice
Gatton College of Pharmacy at East Tennessee State University
Johnson City, Tennessee
FACULTY REVIEWER
Jeffrey P. Bratberg, PharmD, BCPS
Clinical Professor of Pharmacy Practice
University of Rhode Island College of Pharmacy
Kingston, Rhode Island
FINANCIAL DISCLOSURE
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter |
Reported Financial Relationship |
Jeffrey P. Bratberg, PharmD |
Nothing to disclose |
Brandie N. LeBlanc, PharmD/MPH Candidate Class of 2017, BSN |
Nothing to disclose |
Sara T. Melton, PharmD, BCPP, BCACP, PASCP |
Nothing to disclose |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager |
Reported Financial Relationship |
Maya Doe-Simkins, Medical Writer |
Nothing to disclose |
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following JBS International planners and managers, Susan Hayashi and Anne Leopold, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
ACCREDITATION STATEMENTS
PHARMACY
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (0.20 CEUs) of the Accreditation Council for Pharmacy Education.
UAN: 0809-9999-16-277-H03-P
Credits: 2.0 hours (0.20 ceu)
Published: May 23, 2016
Expires: May 23, 2017
Type of Activity: Knowledge
Media: Internet
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 120 minutes
TARGET AUDIENCE
This accredited activity has been designed for pharmacists.
HOW TO EARN CREDIT
During the period May 15, 2016 through May 15, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 75% or higher), your Statement of Credit will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
GOAL
Pharmacists are ideally situated to provide lifesaving education and empowerment to communities to decrease prescription opioid and heroin overdose deaths. Pharmacists are the public's most accessible medication safety experts. Through the use of collaborative prescribing models, pharmacists are able to implement strategies in their communities with naloxone distribution to prevent mortality from opioid or heroin substance use disorders.
EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants should be better able to:
- Summarize the evidence-base and rational for opioid overdose prevention education and the use of naloxone in the community.
- Describe the regulations, statutes, and models relevant to prescribing and dispensing naloxone.
- Discuss the role of the pharmacist in the identification of patients at risk for opioid overdose, and the education of patients and caregivers in overdose risk reduction, recognition, and response.
- Identify opportunities to partner with health departments, boards of pharmacy and medicine, health professional training programs, substance abuse treatment programs, and others to expand access to naloxone via pharmacists.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.